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ABBREVIATIONS 
AC adenylate cyclase 
AcMNPV Autographa californica multiple nucleopolyhedrovirus 
AMP adenosine-5'-monophosphate 
ATP  adenosine-5'-triphosphate 
BacMam a recombinant baculovirus for delivering genes of interest in to 
mammalian cells 
BP base pair 
BRET bioluminescence resonance energy transfer 
B16F10 mouse melanoma cell line B16F10 
cAMP 3'-5'-cyclic adenosine monophosphate 
CFP cyan fluorescent protein 
cGMP 3'-5'-cyclic guanosine monophosphate 
COS-7 African green monkey kidney fibroblast-like cell line COS-7 
CREB cAMP-response-element-binding protein 
DMEM Dulbecco's Modified Eagle's Medium 
DNA deoxyribonucleic acid 
DPBS Dulbecco's Phosphate-Buffered Saline 
EC50 The molar concentration of an agonist that produces 
50% of the maximal possible effect of that agonist. 
EDTA ethylenediaminetetraacetic acid 
EGTA ethylene glycol tetraacetic acid 
ELISA enzyme-linked immunosorbent assay 
Epac exchange protein directly activated by cAMP 
FLIM fluorescence lifetime imaging 
FP fluorescence polarization 
FRET fluorescence (Förster) resonance energy transfer 
FSH follicle-stimulating hormone 
GEF guanine nucleotide exchange factor 
GDP guanosine-5'-diphosphate 
GTP guanosine-5'-triphosphate 
GPCR G protein-coupled receptor 
hCG human chorionic gonadotropin 
HEK293 human embryonic kidney cell line HEK293 
hLH human luteinizing hormone 
IBMX 3-isobutyl-1-methylxanthine 
IC50 The molar concentration of an antagonist that reduces 
the response to an agonist by 50%. 
IP3 inositol-1,4,5-triphosphate 
JEG-3 human choriocarcinoma cell line JEG-3 
MCR melanocortin receptor 
MEM Minimum Essential Medium 
MSH melanocyte-stimulating hormone 
PDE phosphodiesterase   
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PKA protein kinase A 
PLC phospholipase C 
RET resonance energy transfer 
RNA ribonucleic acid 
RPMI Roswell Park Memorial Institute medium 
Sf9 Spodoptera frugiperda cell line Sf9 
YFP yellow fluorescent protein   
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INTRODUCTION 
Pharmacologically active compounds or drugs are inseparable from today’s 
society. The world’s population growing and ageing and the total number of pa-
tients suffering from some sort of disease is constantly rising. Illnesses are 
caused or result in dysregulation of cellular metabolism and signaling. G 
protein-coupled receptors (GPCRs) form a large family of proteins that regulate 
biosignaling between the cells of the human organism. Modulation of GPCRs 
by administration of specific compounds is one of the possibilities to cure or 
alleviate many diseases and more than one third of all prescription drugs are 
targeting GPCRs. 
However, new synthetic compounds need to be carefully designed, selected, 
tested and compared with other compounds of known pharmacological profile. 
Such characterization needs to be performed both in vitro and on living cells 
before entering expensive animal testing. 
There are close to 800 different GPCRs in the human genome. One of the 
common pathways for GPCR signal transduction across the cell membrane is 
modulation of adenyalte cyclase resulting in the production of cyclic adenosine 
monophosphate (cAMP). cAMP is a cellular secondary messenger molecule 
that in turn can activate many downstream signaling proteins. Monitoring chan-
ges in cAMP concentration is one of the direct approaches for detection of 
GPCR activation. Genetically encoded biosensor proteins have proven as suit-
able tools for this task. Such biosensors are applicable in living cells for cAMP 
detection in real time. 
For characterization and functional screening of GPCR ligands cAMP bio-
sensor proteins must be present in the cells expressing the receptor of interest. 
Reliable expression of the biosensor protein enables setting up a robust assay 
for cAMP detection for different GPCR in various cellular systems. Moreover, 
monitoring of cAMP levels in living cells is important for deeper studies of 
GPCR signaling mechanisms. To achieve reliable biosensor protein expression 
for the cellular receptor activation assays we implemented a baculovirus based 
BacMam expression system. 
After successful generation and optimization of the BacMam based assay 
system, we proceeded with the validation of the assay system using different 
GPCRs expressed in different cell lines by characterizing their activation with a 
set of known ligands. We were able to distinguish between full and partial ago-
nists (activators) and were able to monitor both, the increase and the decrease in 
cAMP concentrations in response to receptor activation. The developed bio-
sensor assay was thereafter adapted for detection and quantification of gonado-
tropins from various preparations. 
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1. G PROTEIN-COUPLED RECEPTORS  
With approximately 800 members, GPCRs form the largest family of cell sur-
face receptors. Genes encoding GPCRs account for approximately 2% of the 
human genome (Fredirksson et al., 2003). These proteins are characterized by a 
seven-transmembrane α-helical structure that transduces extracellular signals 
into intracellular effector pathways via heterotrimeric G-protein activation 
(Pierse et al., 2002; Rosenbaum et al., 2009; Heng et al., 2013). GPCRs are 
known to modulate a wide variety of different cellular responses. They respond 
to endogenous neurotransmitters and hormones as well as to exogenous ligands 
and stimuli, eg. therapeutic drugs, photons, tastants, and odorants. More gene-
rally, GPCRs play a critical role in cell growth, differentiation, migration, and 
death. 
Disturbances in GPCR signaling can result in metabolic, immunological, and 
neurodegenerative disorders, but also in cancer and infectious diseases. About 
40% of today’s prescription drugs mediate their effects by modulating GPCR 
signaling pathways (Heng et al., 2013; Garland 2013). Representing a large 
number of therapeutic targets currently in use or in development, the family of 
G protein-coupled receptors is of outmost importance for drug screening and 
discovery. 
GPCRs are commonly divided into five families based on their sequence and 
structural similarity: rhodopsin (family A), secretin (family B), glutamate 
(family C), adhesion and Frizzled/Taste2, with the rhodopsin family being the 
largest and most diverse of these families (Fredriksson et al., 2003; Rosenbaum 
et al., 2009). The ligands for the GPCRs are of wide structural variation; ions, 
organic odorants, amines, peptides, proteins, lipids, nucleotides, and even pho-
tons are able to mediate their message through these proteins. Based on their 
effect on the receptor function, ligands can be classified as full, partial and 
inverse agonists and antagonists. Agonists exert a positive signaling response, 
while inverse agonists reduce the level of basal or constitutive activity below 
that of the unliganded receptor. Antagonists compete and inhibit the binding of 
agonists but do not produce a cellular response (Rosenbaum et al., 2003).  
After agonist binding, a conformational rearrangement of the receptor and 
the subsequent activation of the heterotrimeric G proteins is initiated (Rosen-
baum et al., 2003). These are gunanine nucleotide binding proteins (hence the 
name, G proteins) composed of α-, β-, and γ-subunits. The conformational 
change of the agonist-bound GPCRs catalyzes the exchange of guanidine 
diphosphate (GDP) for guanidine triphosphate (GTP) on the α-subunit (Gα) of 
the G proteins, thereby dissociating Gα the dimeric β-, and γ-subunits (Gβγ). 
The functions of G proteins are regulated cyclically by association of GTP with 
Gα, hydrolysis of GTP to GDP and Pi, and dissociation of GDP. Binding of 
GTP is closely linked with “activation” of the G protein and consequent regu-
lation of the activity of the appropriate effector. Hydrolysis of GTP initiates 
deactivation (Gilman, 1987). 
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In 1994 the Nobel Prize in physiology or medicine was awarded to Alfred G. 
Gilman and Martin Rodbell for their discovery of G-proteins and the role of 
these proteins in signal transduction in cells. In 2012 the Nobel Prize in che-
mistry was awarded to Robert J. Lefkowitz and Brian K. Kobilka for their 
contribution to the studies of GPCRs. This illustrates the fundamental impor-
tance of studies on GPCR signaling. Although many aspects of cellular signal 
transmission have been thoroughly investigated and characterized, much infor-
mation remains elusive. The need for sensitive methods allowing investigation 
of the GPCR mediated signaling processes is driving today’s scientists to 
develop novel analytical approaches or to implement well known techniques in 
an innovative way resulting in new data and information. 
GPCRs vary in structure and function but also in the structure and size of 
their natural ligands. The widest expression of GPCRs in the brain accounts for 
receptors binding the low molecular weight neurotransmitters (Brady et al., 
2011). The biogenic amines such as dopamine, epinephrine, norepinephrine, 
histamine, serotonin and glutamate regulate vital physiological and cognate 
functions via their specific GPCRs. As an example, dopamine receptor targeted 
compounds are significant tools for the management of several neuropsychiatric 
disorders including schizophrenia, bipolar disorder, depression and Parkinson’s 
disease (Carlsson, 2001; Beaulieu and Gainetdinov, 2011; Beaulieu et al., 
2015). There are five receptors for dopamine differing in their expression in the 
organism and the ability to modulate downstream signaling. The most wide-
spread of the dopamine receptors is the D1 subtype. Followed by the D2 and to 
a lesser extent by the D3 receptors that are mainly expressed in limbic areas of 
the brain. Compared to the first three subtypes of dopamine receptors, D4 and 
D5 subtypes exhibit only modest expression patterns in the brain (Beaulieu and 
Gainetdinov, 2011). 
Also widely expressed in the brain and the periphery are peptide receptors. 
Endogenous peptides like melanocortins, opioid peptides, neuropeptide Y, 
galanin and vasopressin regulate pigmentation, food intake, sexual arousal, 
sleep cycle, blood pressure and water retention. Consistent with the variety of 
physiological roles of peptide receptors, the range of conditions in which their 
regulation is distorted includes cardiovascular, endocrine and metabolic dis-
orders. The melanocortin system is composed of five melanocortin receptors 
(MCRs) modulated by the agonists adrenocorticotropic hormone and α, β and γ 
melanocyte-stimulating hormone (MSH), and two naturally occurring anta-
gonists, agouti and agouti-related protein. MCRs are one of the smallest GPCRs 
composed of about 300 amino acid residues (Wikberg et al., 2000; Rodrigues et 
al., 2014). Most widely expressed is the MC1 receptor subtype. It is found in 
the skin and in the brain, in immune cells, adipocytes, pituitary, corpus luteum 
and in placenta. It is primarily responsible for the regulation of skin and hair 
pigmentation, but is also involved in anti-inflammatory actions and regulation 
of pain signaling (Rodrigues et al., 2014). The ligands for the MCR can be 
endogenous peptides (α, β and γ-MSH), synthetic peptides (NDP-α-MSH, MS-
05) or cyclic synthetic peptides (SHU-9119, HS-024) and low molecular weight 
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non-peptide ligands (THIQ) (Sawyer et al., 1980; Hruby et al., 1995; Kask et 
al., 1998; Szardenings et al., 2000; Mutulis et al., 2004). 
A group of GPCRs binding larger peptides and proteins are the hormone 
receptors. Their ligands (up to 40 kDa) can be comprised of several subunits 
that can vary in the level of glycosylation depending on the tissue and the meta-
bolism cycles. Hormone receptors are mostly responsible for regulating hor-
mone production and secretion, growth and endocrine functions. Examples of 
the latter are gonadotropins: follicle-stimulating hormone (FSH), luteinizing 
hormone (hLH), chorionic gonadotropin (hCG). hLH and hCG act via a shared 
GPCR (LH receptor) that regulates diverse reproductive mechanisms that are 
essential for ovulation, early pregnancy and placental function in females as 
well as spermatogenesis and testosterone production in males (Choi and Smitz, 
2014). LH receptor is a glycoprotein consisting of 675 amino acid residues. The 
mature LH receptor has the molecular weight of 85–95 kDa depending on the 
level of glycosylation (Ascoli et al., 2002). Gonadotropins FSH, LH and hCG 
are heterodimers that consist of non-covalently linked α- and β-subunits. Their 
α-subunits of these hormones are identical, but the β-subunits differ to the 
extent that FSH shows no comparable binding affinity or biological activity on 
the LH receptor (Ascoli et al., 2002). 
 
 
1.1. SECONDARY SIGNALING PATHWAYS OF  
GPCR ACTIVATION  
Based on the amino acid sequence homologies of their Gα subunit, heterotri-
meric G proteins are classified into four families: Gαs, Gαi/o, Gαq/11, and Gα12/13 
(Gilman, 1987). Upon activation of GPCRs, each Gα subunit stimulates and 
integrates a distinct signaling pathway. Gαs subunits stimulate the effector 
enzyme adenylate cyclase (AC) to catalyze the production of cAMP from ATP. 
This initiates different cAMP‑dependent cellular pathways leading to the acti-
vation of downstream signaling proteins. In contrast, Gαi subunits inhibit the 
production of cAMP. Gαq/11 subunits activate phospholipase C (PLC), an en-
zyme that cleaves phosphatidylinositol 4,5‑biphosphate into second messen-
gers inositol-1,4,5-triphosphate (IP3) and diacylglycerol. IP3 activates the 
release of Ca2+ stores from endoplasmatic reticulum and diacylglycerol activates 
protein kinase C, promoting further signaling cascades. Gα12/13 subunits act 
through RhoGEF (guanine nucleotide exchange factors) to activate Rho GTPase 
family members and regulate actin cytoskeleton remodeling and cell migration. 
In addition, free Gβγ dimers also activate effector molecules such as ion 
channels and PLC, thus inducing independent signaling pathways (Rosenbaum 
et al., 2003; Lin, 2013). 
Despite extensive studies, a comprehensive characterization of the G 
protein-coupling profile of GPCRs is complicated: for example, some GPCRs 
can couple only to a single type of G protein, whereas many GPCRs couple to a 
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broader range of G protein families depending on the tissue type and the 
developmental stage of the organism (Miyano et al., 2014). 
Aside from the activation of the G proteins, GPCR signaling is also mo-
dulated by G-protein coupled receptor kinases and β-arrestins (Gurevich et al., 
2012; Reiter and Lefkowitz, 2006). The modulation of GPCR signaling by these 
proteins can be divided into three distinct actions: (a) silencing: the functional 
uncoupling of the receptor from its cognate G protein by a mechanism known as 
“homologous desensitization”; (b) trafficking: receptor internalization, “resensi-
tization” and/or degradation; and (c) signaling: the activation or inhibition of 
intracellular signaling pathways independently of heterotrimeric G proteins 
(Reiter and Lefkowitz, 2006). It has been demonstrated, that agonists can 
display functional selectivity where activated receptors are biased to either G 
protein- or arrestin-mediated downstream signaling pathways (Seifert, 2013). 
 
 
1.2. cAMP SIGNALING PATHWAY 
cAMP was first described by Rall et al. (1957), who showed that sympatho-
mimetic amines and glucagon were able to induce the synthesis of a heat-stable 
factor, cAMP, formed by particulate fractions of liver homogenates in the 
presence of ATP and Mg2+ (Beavo and Brunton, 2002; Godinho et al., 2015). In 
the same year Earl Sutherland described this molecule as an intracellular 
“second” messenger that is activated in response to epinephrine (the “first” 
messenger), that cannot pass through the cell membrane (Sutherland, 1972). 
Sutherland was awarded the Nobel Prize in Physiology or Medicine in 1971 for 
his discoveries concerning the mechanisms of the action of hormones (Beavo 
and Brunton, 2002). 
cAMP generation and degradation is regulated by the adenylate cyclase 
(AC) and phosphodiesterase (PDE) families of enzymes, respectively (Tasken 
and Aandahl, 2004; Bender and Beavo, 2006). These enzymes are differentially 
expressed and regulated in different tissues. Both, AC and PDE enzymes are 
responsible for modulation of physiological levels of the second messenger. 
Adenylate cyclases are ATP-pyrophosphate lyases that convert ATP to 
cAMP and pyrophosphate. There are nine mammalian transmembrane AC 
isoforms (AC1-AC9), and one soluble isoform that has distinct catalytic and 
regulatory properties resembling the cyanobacterial enzymes. All isoforms of 
transmembrane ACs are stimulated by the GTP-bound Gαs. GTP-bound Gαi 
protein inhibits AC1, AC5, and AC6 resulting in reduced intracellular cAMP 
content (Sadana and Dessauer, 2009). 
Cyclic nucleotide PDEs are enzymes that regulate the cellular levels of the 
second messengers, cAMP and cGMP, by catalyzing the hydrolysis of the 3’ 
cyclic phosphate bonds resulting in non-signaling AMP and GMP. There are 11 
different PDE families, with each family typically having several different 
isoforms and splice variants. PDEs differ in their structure, kinetic properties, 
modes of regulation, intracellular localization and cellular expression (Bender 
14 
and Beavo, 2006). PDEs also differ in their substrate specificity: PDE4, PDE7, 
and PDE8 are specific for cAMP, PDE5–PDE6, and PDE9 are specific for 
cGMP and PDE1–PDE3 and PDE10–PDE11 hydrolyze both cAMP and cGMP 
(Bender and Beavo, 2006; Godinho et al., 2015). 
cAMP is mostly produced in close proximity to the plasma membrane. 
However, its degradation by specific PDEs underpins compartmentalized cAMP 
signaling in cells and the activation threshold is thus regulated for downstream 
effectors in spatially defined intracellular complexes (Houslay, 2010). The so-
called cAMP microdomains were first visualized in rat cardiomyocytes (Zac-
colo and Pozzan, 2002) 
The first identified downstream target of cAMP was protein kinase A (PKA) 
(Walsh et al., 1968). It was shown that PKA is a heterotetramer composed of 
two regulatory and two catalytic subunits (Corbin and Krebs, 1969). Upon co-
operative binding of four cAMP molecules to the regulatory subunits of PKA 
heterotetramer, the catalytic subunits dissociate from the regulatory dimer and 
are then able to phosphorylate downstream targets. PKA activity results in 
regulation of target enzymes and transcription factors (Tasken and Aandahl, 
2004; Godinho et al., 2015). PKA has served as a prototype for understanding 
protein kinases and the role of phosphorylation as means of modifying the 
activity of proteins (Kandel, 2012). For discoveries concerning the reversible 
protein phosphorylation as a biological regulatory mechanism Edmond H. 
Fischer and Edwin G. Krebs were awarded the Nobel Prize in Physiology or 
Medicine in 1992 (Beavo and Brunton, 2002). 
Intracellular cAMP is also able to directly modulate ion channels (Fesenko et 
al., 1985; Bradley et al., 2005), and specific guanine nucleotide exchange fac-
tors (GEFs). These cAMP responsive GEFs were named exchange proteins 
directly activated by cAMP (Epac) (De Rooij et al., 1998). Epac proteins were 
discovered as mediators of cAMP-induced signaling pathways, which were not 
regulated by either PKA or cyclic-nucleotide-gated channels, the only pre-
viously known cAMP-target proteins (De Rooij et al., 1998, Gloerich and Bos, 
2010). There are two isoforms of cAMP specific GEFs, Epac1 and Epac2, 
differing in the amount of the binding domains for cAMP, one and two, 
respectively (De Rooij et al., 1998 and 2000). The N-terminal cyclic nucleotide 
binding domain of Epac2 binds cAMP with relatively low affinity (~ 90 µM) 
compared to the cAMP binding domain (~ 1.2 µM) proximal to the catalytic 
domain, which is present in both Epac1 and Epac2 (De Rooij et al., 2000). The 
second cAMP binding domain in Epac2 has been speculated to only serve a 
modulatory role (De Rooij et al., 2000; Gloerich and Bos, 2010). Epacs are 
present in most tissues, albeit with different expression levels. Epac1 is highly 
abundant in blood vessels, kidney, adipose tissue, central nervous system, 
ovary, and uterus, whereas Epac2 is mostly expressed in the central nervous 
system, adrenal gland, and pancreas (Gloerich and Bos, 2010). 
In the late 1960s, long-term effects and transcriptional regulation of cAMP 
effectors started to emerge as areas of investigation. Systems in which elevated 
cAMP and the activation of PKA seemed to be coupled to the induction of 
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specific proteins were reported (Wicks et al., 1969). The first transcription 
factor found to be regulated by PKA was the cAMP-response-element-binding 
protein (CREB). It was also the very first transcription factor whose activity 
was shown to be regulated by phosphorylation (Mayr and Montminy, 2001). 
The free catalytic subunits of PKA can diffuse into the nucleus and induce 
cellular gene expression by phosphorylating CREB at serine residue 133 (Gon-
zalez and Montminy, 1989). CREB mediates the activation of cAMP-responsive 
genes by binding as a dimer to a conserved cAMP-responsive element. 
Transcription of cellular genes usually peaks after 30 minutes of stimulation 
with cAMP, coinciding with the time required for the catalytic subunit levels of 
PKA to become maximal in the nucleus (Mayr and Montminy, 2001). 
As discussed above, ligands of different GPCRs represent a variety of mole-
cules of very different structure and size (low molecular weight molecules, e.g. 
dopamine, oligopeptides, e.g. melanocortins, large hormone proteins, e.g. 
gonadotropins). The cellular responses may be very different for these ligands 
and their receptors, but if coupled to the Gαs system, elevation of cellular cAMP 
level is the common first step in the signaling cascades. One of the central tasks 
of this study was setting up a system for characterization of GPCR signaling 
upon receptor activation of ligands with various structures. GPCRs investigated 
in this study (dopamine, melanocortin and gonadotropin receptors) are all 
coupled either to the Gαs or to Gαi proteins, stimulating or inhibiting cellular 
cAMP synthesis respectively. For real-time detection of receptor activation in 
living cells, an assay for measurement of cAMP levels was implemented.  
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2. METHODS FOR cAMP DETECTION 
The need of assaying cAMP became an issue almost immediately after disco-
vering of the new second messenger molecule in 1957. Sutherland’s original 
assay, which was the only one available for more than ten years, was based on 
the ability of cAMP to activate glycogen breakdown in vitro. The assay de-
pended on the purification of several enzymes and varied with the characte-
ristics of the dog-liver supernatant fraction that contained the necessary protein 
kinases for cAMP binding (Cook et al., 1957; Beavo and Brunton, 2002). Mea-
suring of the cellular response to the extracellular agents provided a new level 
of scientific analysis and compound characterization. Research focused on 
development of new, faster, reliable and more sensitive assays carried on for 
half a century and is still very timely today. 
 
 
2.1. RADIOACTIVELY LABLED  
cAMP ACCUMULATION ASSAYS 
A considerable progress in cAMP detection was achieved more than a decade 
after the first measurements of cAMP, when a protein-binding assay (Gilman, 
1970) made the cellular in vitro studies more accessible. Gilman’s procedure 
was easy and cheap, and could detect 0.1 pmoles of cAMP, which is sensitive 
enough for most purposes, because basal levels of cAMP are ~ 5 pmoles/mg of 
cell protein (Beavo and Brunton, 2002). The assay used a commercially avail-
able ligand, [3H]cAMP and only one protein, the cAMP-sensitive protein 
kinase, needed to be prepared. Assay conditions were such that a binding 
constant approaching 1 µM was obtained (Gilman, 1970). This assay was wide-
ly used and improved during several decades (Nordstedt et al., 1990; Vonk et 
al., 2008). 
One of the most direct approaches to monitoring cAMP generation from 
ATP in living cells is to follow this conversion by pre-labeling cellular adenine 
nucleotide pool with [3H]adenine. After stimulating the cells with agonist, 
column chromatography is used to separate [3H]cAMP from all other tritium-
labelled adenine derivatives (Huang et al., 1971; Donaldson et al., 1988; Hill et 
al., 2010). This method provides a direct read-out of [3H]cAMP accumulation, 
but is relatively time-consuming. Also, concern that is often raised with a radio-
active readout of the accumulation of any intracellular second messenger such 
as cAMP, is that it is a measure of turnover rather than absolute levels (Hill et 
al., 2010). 
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2.2. IMMUNOASSAYS FOR cAMP DETECTION 
Immunoassays for cAMP accumulation measurements follow a general prin-
ciple, with changes in intracellular cAMP being detected by the competition 
between cellular cAMP and a labelled form of cAMP for binding to an anti-
cAMP antibody (Brooker et al., 1978; Williams, 2004). Same principle was 
used in the protein-binding assay (Gilman, 1970; Nordstedt et al., 1990), where 
instead of a specific antibody, PKA binding and subsequent sequestration of the 
complex was used for cAMP quantification. 
The radioimmunoassay developed by Harper and Brooker in 1975 brought 
the sensitivity for cyclic nucleotide measurements into the femtomole range. 
They improved the assay by acetylating the cyclic nucleotides at the 2' position 
with acetic anhydride. This was especially important for measuring cGMP, 
which often exists at the level of one tenth of the tissue content of cAMP 
(Beavo and Brunton, 2002). 
Homogeneous radiometric assays, such as scintillation proximity assays 
(Biosciences Amersham, 1996) and Flashplate® technology (NEN Life Science, 
1998) enable the direct detection of [125I]cAMP captured by the antibody in close 
proximity to a solid scintillate surface. These methods are fast and have high 
reproducibility. There are clear advantages over more traditional radiometric 
enzyme-linked immunosorbent assays (ELISAs) in terms of convenience, 
because the stimulation and detection can be carried out in the same well (Hill et 
al., 2010). Yet, the radiometric technologies started to be superseded in the early 
2000’s with emerging of safer and cheaper methods of non-radiometric read-outs, 
which were more readily miniaturized (Williams, 2004). Most pharmaceutical 
company laboratories prefer to employ fluorescent or luminescent assays due to 
safety, cost and throughput considerations (Hill et al., 2010). 
One of the first fluorescent technologies to emerge was the fluorescence 
polarization (FP) technology. cAMP detection is based on a decrease in the 
extent of molecular rotation of a fluorescently labelled cAMP that occurs 
following binding to the larger anti-cAMP antibody (Williams 2004). The assay 
detects cytoplasmic cAMP content exposed by cell lysis (Prystay et al., 2001). 
FP assays are relatively insensitive to low levels of cAMP, with detection limits 
in the range of 100 fmol (Hill et al., 2010). 
During the 2000’s more fluorescent and luminescent technologies emerged 
to overcome the issues of speed, sensitivity and compound interference that 
posed as shortage in FP assays. Some of these assays rely on chemiluminescent 
proximity (ALPHAScreen®, Perkin Elmer), electro-chemiluminescence de-
tection (Meso Scale Discovery) and time resolved fluorescence resonance 
energy transfer (FRET) (HTRF®, Cis Bio & LANCE®, DELFIA®, Perkin 
Elmer). In assays employing HTRF technology, the anti-cAMP antibodies are 
labelled with europium cryptate and the cAMP is labelled with a modified 
allophyocyanin. When these two fluorescent molecules are in close proximity, 
FRET occurs and long lifetime fluorescence is emitted at two different wave-
lengths (Williams 2004). All these technologies rely on high quality antibodies; 
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vary in terms of their costs, reader compatibility and impact of compound 
interference (Williams, 2004; McLoughlin et al., 2007; Hill et al., 2010). 
 
 
2.3. REPORTER-GENE ASSAYS 
In reporter-gene assays receptor-mediated changes in intracellular cAMP con-
centrations are detected via changes in the expression level of a particular gene 
(the reporter), the transcription of which is regulated by the transcription factor 
cAMP response-element binding protein (CREB) binding to upstream cAMP 
response elements (Naylor 1999, Williams, 2004). Based upon the splicing of 
transcriptional control elements to a variety of reporter genes (with easily mea-
surable phenotypes), the assay “reports” the effects of a cascade of signaling 
events on gene expression inside cells (Naylor, 1999). Products of various genes 
have been used as readout of reporter-gene assays (e.g. β-galactosidase, green 
fluorescent protein, luciferase and β-lactamase). Depending on the chosen 
reporter-gene, the readout can be a change in color (upon substrate chromo-
phore cleavage), change in fluorescence intensity or the light produced as a 
byproduct of the chemical reaction. Due to additional signal amplification (the 
readout is resulting at the end of the cellular signaling cascade) and the fact that 
these assays generally require longer incubation times to allow for the gene 
transcription event, reporter-gene assays can provide a significant advantage 
over accumulation assays for the detection of weak agonists. However, attention 
should be paid when evaluating ligands with partial agonist activity. In most 
reporter gene systems these molecules are likely to manifest as full agonists 
because of the signal amplification (Baker et al., 2003, Hill et al., 2010). 
 
 
2.4. BIOSENSORS FOR cAMP DETECTION 
Most of the methods for cAMP detection discussed above rely on measuring the 
accumulated pool of the second messenger. Moreover, most of the methods are 
limited to end-point measurements in cell lysates and therefore generally 
contain little temporal and no spatial information. The need for real-time moni-
toring of the signaling events was evident. In the beginning of 2000’s several 
laboratories set out to develop methods for monitoring GPCR activation and 
signaling in intact cells and ultimately also in intact organs or organisms (Lohse 
et al., 2007). In 2008, Osamu Shimomura, Martin Chalfie, and Roger Tsien 
received the Nobel Prize in Chemistry for their discovery of the green fluore-
scent. The reason for such success lies on the fact that soon after introducing of 
the potential of the genetically encoded fluorescent proteins (Heim and Tsien, 
1996; Matz et al., 1999) many laboratories have utilized these to develop 
fluorescent biosensors. These developments have permitted the visualization of 
cellular processes turning fluorescent proteins into key tools of biology and 
biochemistry (Newman et al., 2011; Okumoto et al., 2012). 
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Humankind has known the use of biosensors for hundreds of years. For 
example, the canary in a coalmine is a sensor for detection of toxic gases as 
methane or carbon monoxide. However, such assay is not quantitative and the 
sensor may not survive the assay. Today, biosensors are engineered constructs 
that couple the detection of a biochemical event to an optical signal (Clister et 
al., 2015). Besides quantitative measurements of concentration and distribution 
of biomolecules (e.g. cellular second messengers), there are also other potential 
applications of biosensors. Discovery and modeling of metabolic pathways for 
systems biology as well as implementation of biosensor technology to comple-
ment other quantitative techniques of analytical chemistry (Okumoto et al., 
2012). It is however always important to keep in mind that the introduction of a 
biosensor will at least to some extent affect the cellular environment and 
possibly modify cellular behavior. 
The biosensor system generally consists of a sensory domain that recognizes 
the analyte of interest and the response domain that is responsible for yielding a 
detectable signal. For a sensor to reliably report the dynamics of the analyte, the 
affinity and dynamic range of the sensor must match the level of analyte and the 
kinetics of association and dissociation need to be fast enough to capture tran-
sient accumulations (Okumoto et al., 2012). 
 
 
2.4.1. RESONANCE ENERGY TRANSFER  
BASED BIOSENSORS 
Non-radiative fluorescence and bioluminescence resonance energy transfer 
processes, FRET and BRET, are based on energy transfer between two closely 
spaced probes (Boute et al., 2002; Lohse et al., 2007). The prototypical reso-
nance energy transfer (RET) biosensor consists of a recognition element fused 
with a pair of fluorescent or bioluminescent proteins capable of RET. A confor-
mational change in the recognition element can be exploited to induce change in 
the distance and orientation between the donor and acceptor molecule resulting 
in the change in RET efficiency (Lohse et al., 2007; Okumoto et al., 2012). 
FRET from one dye to another is a quantum mechanical process occurring if 
these two chromophores are in close proximity (less than 10 nm apart). A 
German chemist Theodor Förster (Förster, 1948) first reported this pheno-
menon. The efficiency of energy transfer is given as E = (1 + (R / R0)6)–1, where 
R is the inter-dye distance, and R0 is the Förster radius at which E= 0.5 (Roy, 
Hohng and Ha, 2008, Lakowicz, 2007). R0 (in Å) = 0.211(κ2n-4QDJ(λ))1/6. As 
shown, R0 depends on the orientation factor (κ) accounting for the dipole-dipole 
orientation of donor and acceptor; the refractive index of the medium (n); the 
quantum yield of the donor (QD) and the spectral overlap integral (J) between 
the emission of the donor and excitation of the acceptor fluorophores 
(Lakowicz, 2007). Relative FRET efficiency can be determined from the ratio 
of acceptor to donor fluorescence when only the donor fluorophore is excited. 
Alternatively, the acceptor molecules can be photobleached, and the relative 
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increase in donor emission can be used as a measure of FRET efficiency 
(Willoughby and Cooper, 2008). A limitation of FRET is the requirement for 
external illumination to initiate the fluorescence transfer. BRET is a similar 
quantum mechanical process to FRET, but occurring if bioluminescent luci-
ferase (usually from Renilla reniformis) produces initial photon emission com-
patible with the acceptor fluorophore, which re-emits light at another 
wavelength (Boute et al., 2002).  
Several cAMP biosensors based on BRET (Prinz et al., 2006; Jiang et al., 
2007) have been developed, still most of the widely used sensors rely on FRET. 
Among the FRET-based cAMP sensors the first generation sensors depended on 
PKA (Adams et al., 1991; Zhang et al., 2001; Zaccolo and Pozzan, 2002) and 
on cAMP regulated ion channels (Fagan et al., 2001; Rich et al., 2001). Yet 
probes based on Epac protein (DiPilato et al., 2004; Nikolaev et al., 2004; 
Ponsioen et al., 2004) proved to be most advantageous due to their mono-
molecular structure and uniform cellular expression. Epac-based probes have 
been much improved since the development of their prototypes (Nikolaev et al., 
2006; van der Krogt et al., 2008; Klarenbeek et al., 2011) resulting in an array 
of cAMP sensors with improved sensitivity, signal-to-noise ratio, dynamic 
range and spatiotemporal resolution (Willoughby and Cooper, 2008). Very 
common fluorophores with overlapping spectra used in cAMP biosensors are 
the GFP variants cyan (CFP) and yellow (YFP) fluorescent proteins (Nikolaev 
and Lohse, 2006; van der Krogt et al., 2008; Willoughby and Cooper, 2008). In 
the first cAMP biosensor however, synthetic dyes were used a FRET pair. The 
biosensor consisted of catalytic (C) and regulatory (R) subunits of PKA, 
chemically labeled with fluorescein (Fl) and rhodamine (Rh), respectively. The 
sensor was termed FlCRhR reflecting its composition (Adams et al., 1991). 
Fluorescent proteins as well as genetically encoded sensors consist of poly-
peptide chains and are inherently sensitive to changes in ionic strength and pH 
(Okumoto et al., 2012). Thorough studies have been conducted and several 
FRET pairs compared to account for these issues as well as for protein photo-
stability, brightness and proper maturation as well as low phototoxicity (van der 
Krogt et al., 2008; Rusanov et al., 2010; Lam et al., 2012; Klarenbeek et al., 
2011 and 2015). 
The recognition elements of cAMP sensors are composed of polypeptides 
that are native to the cells. If unaltered these may interfere with cellular func-
tions (Okumoto et al., 2012). To avoid this issue, mutations that make the 
recognition elements catalytically inactive have been introduced in several 
cAMP biosensors (Ponsioen et al., 2004; van der Krogt et al., 2008; Klarenbeek 
et al., 2011). The other approach has been the fusion of only the short peptide 
chain responsible for the binding of cAMP between the FRET pair, therefore 
eliminating the need to use full-length proteins (Nikolaev et al., 2004). 
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2.4.2. Epac2-camps BIOSENSOR 
In this thesis, two biosensors were used for measurements of cAMP levels in 
living cells. The first generation Epac2-camps construct consists of enhanced 
cyan fluorescent protein (eCFP) and enhanced yellow fluorescent protein 
(eYFP) fused directly to the high-affinity cAMP-binding domain of Epac2 pro-
tein (Kd ~ 1.2 µM; De Rooij et al., 2000). Excitation of the eCFP at a wave-
length of 436 nm leads to eCFP emission at ~ 480 nm as well as to eYFP 
emission at ~ 525 nm (Nikolaev et al., 2004). The fluorimetrically measured 
EC50 for Epac2-camps was 0.92 ± 0.07 µM, which is well suited for measure-
ments of physiologically relevant cAMP concentrations (from sub-micromolar 
in the resting state up to 10–100 µM upon adenylate cyclase activation; 
Klarenbeek et al., 2011). At the time, this novel sensor had several advantages 
compared to the former PKA-based biosensors and cAMP accumulation assays. 
Epac2-camps contains only one binding site for cAMP thus lacking binding 
cooperativity (in PKA-based biosensors four cAMP molecules must bind to the 
sensor to induce dissociation and the subsequent change in FRET). Epac2-
camps sensor is uniformly distributed throughout the cytosol and has no 
catalytic properties or interactions with other cellular proteins (Nikolaev et al., 
2004). The specificity of the decrease in FRET in response to cAMP was 
demonstrated in vitro by using Epac2-camps purified from Spodoptera 
frugiperda (Sf9) cells. It was shown that other nucleotides were recognized only 
weakly (AMP, > 10 mM; ATP, 2.5 ± 0.4 mM; cGMP, 10.6 ± 0.4 µM) (Niko-
laev et al., 2004). A direct comparison of Epac2-camps with the tetrameric PKA 
system (Zaccolo and Pozzan, 2002) in Chinese hamster ovary cells uncovered 
that Epac2-camps reacted to adenylate cyclase stimulation much more rapidly 
in accordance with the faster activation kinetics of the new indicator measured 
in vitro (Nikolaev et al., 2004). The response of the Epac-based sensor is 
limited by the kinetics of cAMP production, whereas the tetrameric PKA sensor 
is also limited by activation kinetics of the sensor itself (binding of four cAMP 
molecules and the subsequent subunit dissociation). 
Due to the suitable affinity for cAMP, convenient FRET pair for detection of 
fluorescence intensity with our equipment, no kinetic limitations originating 
from the biosensor itself and the demonstrated applicability of the biosensor in 
many different cell lines, we selected Epac-camps as the biosensor for detection 
of cAMP upon GPCR stimulation. The cDNA construct of the biosensor was 
kindly provided by Professor Marin J. Lohse from University of Würzburg. 
 
 
2.4.3. TEpacVV BIOSENSOR 
As time went on and many laboratories were successfully using the developed 
cAMP biosensors, scientists continued to improve and develop the biosensors. 
Starting from the biosensor variant based on the partially truncated Epac1 
protein (Ponsioen et al., 2004), several “second generation” cAMP biosensors 
were developed by systematic variation of the donor and acceptor fluorescent 
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proteins (van der Krogt et al., 2008). By tilting of the dipole of the acceptor 
proteins FRET efficiency was improved (van der Krogt et al., 2008). This was 
achieved by relocating the amino- and carboxyl termini of the acceptor fluoro-
phore to alternative locations on the surface of the fluorescent protein barrel, so-
called circular permutation. During the studies by van der Krogt et al., the 
dynamic range of the biosensor was improved, if fluorescent donors were pre-
sented with duplicate (tandem) acceptors. The effective absorption of the larger 
acceptor construct is increased and the two fluorophores in a tandem acceptor 
are likely to be oriented differently, thereby easing on the requirement of donor-
acceptor dipole alignment (van der Krogt et al., 2008). It was found that 
incorporation of Venus in the cAMP biosensor cured pH- and UV-sensitivity of 
the probe. Using the tandem acceptor consisting of Venus and circularly per-
mutated (cp173Venus, presenting the acceptor protein at a favorable angle) 
yielded the widest FRET span of 36% upon full AC stimulation in individual 
cells (van der Krogt et al., 2008). 
Replacing enhanced CFP protein with mTurquoise, a very bright CFP 
variant (Goedhart et al., 2010) resulted in a “third generation” cAMP sensor, 
mTurquoiseΔ-Epac(CD,ΔDEP)-cp173-Venus-Venus, called TEpacVV (Klarenbeek 
et al., 2011). In ratiometric fluorescence intensity based assays the dynamic 
range of the new sensor significantly outperforms previous versions: maximal 
FRET change upto 50% in individual cells. Moreover, due to the single-expo-
nentially decaying donor fluorophore the sensor is well suited for both time-
domain and frequency-domain fluorescence lifetime imaging (FLIM) (Klaren-
beek et al., 2011). Due to clear outperformance of TEpacVV over the “first gene-
ration” Epac2-camps biosensor we switched to the “third generation” construct 
in the studies of GPCR systems. The cDNA construct was kindly provided by 
Dr. Kees Jalink from The Netherlands Cancer Institute. 
 
 
2.4.4. METHODS FOR FRET DETECTION 
The degree of FRET can be measured by various approaches, of which the most 
popular is represented by simple fluorescence ratiometry (Sprenger and 
Nikolaev, 2013). This method relies on the sensitized emission of the acceptor 
fluorophore when excited by a donor via FRET. In this case, emission inten-
sities of the donor and the acceptor molecules upon donor excitation are 
detected, and the FRET signal is calculated on a donor/acceptor or acceptor/ 
donor ratio. Quantitative FRET determinations derived from intensity measure-
ments require an accurate reference for the acceptor-free donor signals and are 
difficult to achieve in practice (Jares-Erijman and Jovin, 2003; Lohse et al., 
2012). Yet problems like spectral bleed-through and cellular background fluore-
scence can be overcome if the relative change of FRET is calculated from the 
donor/acceptor ratio. Taken that the contributions of spectral bleed-through and 
background fluorescence are the same before and after cell treatment, dividing 
the intensities results in data normalization during the calculation of FRET 
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change. This rough change in FRET signal can then be plotted against the 
various concentrations of the compound eliciting the measured effect. 
Another popular method for FRET detection is acceptor photobleaching. 
This approach requires a microscope equipped with a laser for “turning off” of 
the acceptor in the FRET pair. After bleaching of the acceptor with bright light, 
emission of donor increases and this increase corresponds to FRET efficiency 
(Lohse et al., 2012). 
The determination of fluorescence lifetime, either in the time or in the fre-
quency domain, is one of the most direct measures of FRET (Jares-Erijman and 
Jovin, 2003). Upon FRET the lifetime of the donor fluorescence decays more 
compared to the acceptor lifetime. The change in FRET efficiency can be 
detected by the change in donor lifetime only (Jares-Erijman and Jovin, 2003). 
FLIM is relatively insensitive to variations in fluorophore concentration and 
optical path length. In general, the method of detection can dictate the comple-
xity of the probe/object. By using FLIM combined with total internal reflection 
microscopy one can concentrate on the membrane region allowing single mole-
cule detection with high data sampling (Roy, Hohng and Ha, 2008). With 
FLIM, much higher spatio-temporal resolution is achievable compared to 
experiments relying on detection of fluorescence intensities. Since FLIM 
detection if focused on donor lifetime only, there is no need for additional 
controls (van der Krogt et al., 2008; Becker 2012). 
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3. RECOMBINANT GENE EXPRESSION 
To use genetically encoded biosensors in experiments on living cells, the DNA 
construct of the biosensor must be delivered into the cells of interest. There are 
many methods for expression of recombinant DNA in eukaryotic cells. Most 
popular is the use of transient transfection methods like calcium phosphate 
precipitation (Graham and Van der Eb, 1973) or complex formation with catio-
nic lipophilic reagents like polyethylene imine (Boussif et al., 1995) or 
diethylethanolamine-dextran (Schenborn and Goiffon, 2000). If the sensors are 
used in single-cell microscopy experiments, these methods are very suitable. 
Inhomogeneous expression levels do not pose problems, because the cells of 
suitable biosensor expression can be selected by applying a threshold value. 
Since only a small number of cells are required there are no considerable cost 
issues regarding purified DNA and the transfection reagents. 
However, for applications where large number of cells with a comparable 
transgene expression levels are desired, transient transfection methods are not 
optimal due to the cumulative high cost of material and variance of the trans-
fection efficiency. 
For the long-time transgene expression, generation of a cell line stably 
expressing the protein of interest can be achieved by co-transfection of a 
marker-gene (for antibiotic resistance). Upon addition of the selection anti-
biotics, the cell population where the transgene has been integrated into the 
genome can be identified and cultured. This method however is not optimal for 
all transgenic constructs. In case of cAMP biosensor constructs, the prolonged 
presence of non-native protein binding the second messenger molecules could 
interfere with normal cellular processes.  
In nature, most efficient and highly evolved mechanisms for infecting cells 
are the viruses. There are many different methods developed to employ their 
high gene delivery efficiency. Commonly, virus-based gene delivery is ac-
complished by using replication-deficient RNA or DNA viruses containing the 
gene of interest, but with the disease-causing sequences deleted from the viral 
genome (Kamimura et al., 2011). Many viral vectors have been utilized for 
transgene delivery including adenovirus, adenoassociated virus, lentivirus, 
retrovirus, Semlinki forest virus, baculovirus, pox virus, herpes simplex virus, 
Epstein-Bar virus, etc. Each of these viruses has its advantages and dis-
advantages, so which to use for a particular experiment may depend on multiple 
factors, including insert size, titer required, target gene expression level and 
target cell type (Walter and Stein, 2000). The primary feature of RNA-based 
viral vectors, such as retroviruses, is that they are capable of long-term trans-
gene expression through gene integration. DNA-based viral vectors normally 
result in transgene expression in episomal form without integration (Kamimura 
et al., 2011). However with the use of viral vectors higher demands on the 
laboratories (Biosafety Level 2) are encountered. The viral constructs are not 
trivial to obtain and many of the viral systems have high maintenance costs. 
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3.1. BACMAM TECHNOLOGY 
Baculovirus infects insects in nature and is non-pathogenic to humans (Bio-
safety Level 1), but can transduce a broad range of mammalian and avian cells. 
Baculoviruses are a diverse group of DNA viruses capable of infecting more 
than 600 insects, among which Autographa californica multiple nucleopoly-
hedrovirus (AcMNPV) is the best characterized and most extensively em-
ployed. AcMNPV contains a circular double stranded DNA genome of approxi-
mately 134 kBP (Chen et al., 2011). Baculovirus cloning capacity is as large as 
38 kBP, thus allowing for the insertion of multiple genes and regulatory 
elements. Baculovirus–insect cell expression system has been one of the most 
widely used systems for routine production of recombinant proteins during the 
past 30 years (Kost et al., 2005; Chen et al., 2011). Many advances have been 
achieved during this time. Baculoviruses have been used in pseudotyped viral 
vaccine development (Wu et al., 2009; Cox, 2012) and been implemented as 
gene delivery vehicles for diverse biomedical applications (Paul et al., 2014). 
The possibility to display foreign proteins on the surface particles improved 
GPCR binding studies (Veiksina et al., 2014) and the insertion of mammalian 
expression cassettes in baculoviruses has eanbled efficient transgene expression 
in different mammalian cells (Kost and Condreay, 2002; Papers I–IV). 
The so-called BacMam system and employs a baculovirus vector with the 
cytomegalovirus promoter to drive the expression of proteins in mammalian 
cells. This approach provides many advantages such as high transduction rates; 
protein expression levels that can be adjusted by viral dose; low cytotoxicity to 
host cells; safety in production and handling; compatibility with a broad range 
of cells, including primary and stem cells; and, importantly, the ease and con-
venience of use (Kost and Condreay, 2002; Kost et al., 2005). 
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4. AIMS OF THE STUDY 
The GPCRs regulate thousands of vital processes in the human organism. Many 
of the rare and the common diseases are caused by distortions in cellular 
signaling or metabolism: Some of these illnesses can be treated or the symp-
toms alleviated by GPCR-targeted compounds. Thus, the search for GPCR-spe-
cific drugs is constantly ongoing and the need for reliable GPCR activation 
assays to test for biological activity of novel compounds is evident. 
The general aim of this work was the development and validation of cAMP 
biosensor assay for characterization of activities of different GPCR ligands. 
Several particular tasks were raised within the study: 
 
 Generation, optimization and validation of the BacMam expression system 
for the cAMP biosensor. Achieving reliable protein expression levels in 
different cell lines.  
 Optimization of the transduction of mammalian cells with the generated 
BacMam virus. 
 Generation of cAMP biosensor based assay system for screening of biolo-
gical activities of novel ligands of different GPCRs stably expressed in parti-
cular cell lines. 
 Implementation of the cAMP biosensor assay for quantification of active 
forms of gonadotropins in various preparations. 
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5. MATERIALS AND METHODS 
Cell lines and cell culture 
Spodoptera frugiperda cells (Sf9) (Invitrogen Life Technologies) were cultured 
in suspension with EX-CELL® 420 growth medium (Sigma-Aldrich GmbH) in 
27 °C incubator in non-humidified environment. 
All mammalian cell lines were grown as an adherent monolayer and main-
tained at 37 °C and 5 % CO2 in a humidified incubator in the appropriate 
growth medium supplemented with 10 % fetal bovine serum, 100 U/ml peni-
cillin, 0.1 mg/ml streptomycin. All media, Dulbecco’s Phosphate-Buffered Sa-
line (DPBS) and trypsin were also from PAA Laboratories. Fetal bovine serum 
was form Gibco, Invitrogen Life Technologies. 
B16F10 mouse melanoma cell line (Invitrogen Life Technologies) was 
cultured in Roswell Park Memorial Institute (RPMI) medium. Human embryo-
nic kidney HEK293 cell line (American Type Culture Collection, ATCC® 
CRL-1573™) was cultured in Dulbecco’s Modified Eagle’s Medium (DMEM). 
JEG-3, human choriocarcinoma cell line clone 3 (Kohler and Bridson, 1971) 
(American Type Culture Collection, ATCC® HTB-36™) was cultured in 
Minimum Essential Medium (MEM). African green monkey kidney fibroblast-
like COS-7 cell line expressing the recombinant human LH receptor (Müller et 
al. 2003) was kindly provided by Manuela Simoni, University of Modena and 
Reggio Emilia, Italy. COS-7 cells were cultured in DMEM/Ham’s F12 
Medium. 
 
GPCR ligands 
Dopamine was from Sigma-Aldrich GmbH. Human, highly purified recombi-
nant LH (r-hLH; Luveris) and CG (r-hCG; Ovitrelle), human urinary CG (u-
hCG; Pregnyl) and recombinant follitropin alfa (r-FSH; Gonal-F) were from 
Merck Serono Europe Limited. Initial concentrations: Luveirs 187.5 IU/ml = 8.7 
µg/ml; Ovitrelle 5780 IU/ml = 500 µg/ml; Pregnyl 5000 IU/ml = 432.5 µg/ml; 
Gonal-F 600 IU/ml = 44 µg/ml. All MC1 receptor peptidic ligands were from 
Bachem, Switzerland: 
  
α-MSH: Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2; 
β-MSH: Asp-Glu-Gly-Pro-Tyr-Arg-Met-Glu-His-Phe-Arg-Trp-Gly-Ser-Pro-Pro-Lys-Asp-OH; 
NDP-α-MSH: Ac-Ser-Tyr-Ser-Nle-Glu-His-DPhe-Arg-Trp-Gly-Lys-Pro-Val-NH2; 
MS-05: Ser-Ser-Ile-Ile-Ser-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2; 
SHU-9119: Ac-Nle-c[Asp-His-D-Nal(2’)-Arg-Trp-Lys]-NH2; 
HS-024: Ac-c[Cys-Nle-Arg-His-D-Nal(2’)-Arg-Trp-Gly-Cys]-NH2. 
 
3-isobutyl-1-methylxanthine (IBMX) used to inhibit phosphodiesterase activity 
was from Sigma-Aldrich GmbH. Forskolin used to directly activate adenylate 
cyclases was from Tocris Bioscience. 
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Plasmid construction and generation of BacMam virus 
The expression vector Epac2-camps (Nikolaev et al. 2004) was kindly provided 
by Professor Marin J. Lohse from University of Würzburg. The expression 
vector mTurqDel-EPAC(dDEPCD)-cp173Venus(d)-Venus(d) (H74 or TEpacVV) 
(Klarenbeek et al. 2011) was kindly provided by Dr. Kees Jalink from The 
Netherlands Cancer Institute. Both biosensor constructs under the control of the 
cytomegalovirus promoter were cloned from the pcDNA3.1(+) vector into the 
pFastBac™1 vector (Invitrogen Life Technologies) using the restriction en-
zymes (Thermo Scientific) Bst1107I (BstZ17I) and Bsp68I (NruI) for 
pcDNA3.1(+) and Eco105I (SnaBI) and KspAI (HpaI) for pFastBac™1, respec-
tively. The polyhedrin promoter was removed from the pFastBac™1 vector to 
ensure low promoter interference during virus amplification. The obtained 
pFastBac-cAMP-biosensor constructs were transformed into DH10Bac™ 
competent cells (Invitrogen Life Technologies) for the production of recombi-
nant bacmid DNA. PCR-verified bacmid DNA was then transfected into Sf9 
insect cells using 4 equivalents of ExGen 500 (Fermentas) to prepare BacMam 
virus stocks according to the Invitrogen Life Technologies Bac-to-Bac® expres-
sion system manual. P1 viral stocks were amplified and the titers were 
determined by cell size based assay using Sf9 cells. P1 viral stocks were stored 
at -80 ºC until further amplification. P2 and P3 viral stocks were aliquoted and 
stored at -80 ºC or concentrated 10 times by centrifugation at 40000  g and 
stored at 4 ºC until the day of the experiment. 
 
Determination of viral titers by a cell size based assay 
The viral titers were determined using a cell size-based assay (Paper III). Sf9 
cells were seeded on 24-well cell culture plates at 0.2×106 cells/well in 250 μl 
of EX-CELL 420 cell culture medium 30–60 minutes prior to infection. 250 μl 
of dilution samples were added to wells (3-fold serial dilutions of harvested 
virus supernatant or of concentrated virus in EX-CELL 420 medium). The cells 
were incubated in the presence of the virus for 24 h and thereafter the average 
cell diameter was determined using a Beckman Coulter cell counter. To calcu-
late the titer, the average cell diameter was plotted versus the log (virus 
dilution) to obtain the sigmoidal dose-response curve. The virus concentration 
in infectious units per ml (IU/ml) was calculated using equation (1): 
 
ܸ݅ݎݑݏ	ܿ݋݊ܿ݁݊ݐݎܽݐ݅݋݊	(ܫܷ/݈݉) =
భ
ಶವఱబ×ହ଴%	௢௙	௜௡௙௘௖௧௘ௗ	௖௘௟௟௦
௏     (1), 
 
where V – sample volume in wells in milliliters (here 0.5 ml); ED50 – 50% 
effective virus dilution corresponding to dilution at which the average cell dia-
meter has changed 50%; 50% of infected cells – 50% of the cells in wells at the 
time of infection given that the number of cells is roughly equal to the number 
of infective viral particles and the proportion of secondary infection is minimal 
(Janakiraman et al., 2006). 
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[3H]cAMP competition binding assay 
80–90 % confluent cells on 100 mm polylysine coated petri dishes (Nunc) were 
detached and the medium was replaced by DPBS. Cells were divided to aliquots 
of 0.3  106 cells / assay tube and stimulated upon addition of 10 X ligand 
solution in the final assay volume of 200 l. The reaction was carried out for  
30 min at 37 ºC and was stopped by adding 200 µl of 1 M ice-cold HClO4 
solution. The lysates were stored on ice for 60 minutes and then neutralized 
with 200 µl of 1 M ice-cold KOH solution. 
The content of accumulated cAMP in the samples was measured by compe-
tition binding with [3H]cAMP to cAMP binding protein (extracted from bovine 
adrenal glands) as previously described by (Nordstedt et al. 1990, Vonk et al. 
2008). Samples or calibration standards + [3H]cAMP + cAMP binding protein 
were incubated for 60 min at +4 ºC. All solutions prepared in Brown Buffer (50 
mM Tris-HCl, pH 7.4; 100 mM NaCl, 10 mM EDTA, 8 mM Theophylline and 
6 mM DTT) in the final assay volume of 200 l. All determinations were 
performed in triplicates. The bound [3H]cAMP was determined by fast filtration 
through thick GF/B glass fiber filters (Whatman) using a FilterMate Harvester 
(Model D961962, Perkin Elmer). After five washes with ice-cold phosphate 
buffer (20 mM K-phosphate, 100 mM NaCl, pH 7.4), filter mats were dried in a 
microwave oven and impregnated with a MeltiLex™ B/HS scintillant using a 
MeltiLex® Heatsealer. Filter-bound radioactivity was counted using a 
PerkinElmer/Wallac MicroBeta TriLux 1450 LSC Luminescence Counter. The 
cAMP concentrations in the samples were determined by interpolating the 
detected values using the calibration curve obtained in the same assay. 
 
cAMP biosensor assay 
60–80 % confluent mammalian cells on 100 mm polylysine coated petri dishes 
(Nunc) were transduced with 250–500 μl/dish of 10  viral stock (multiplicity 
of infection: 100–400) in 4 ml serum free growth medium for 3 h at 37 °C. 
Thereafter the medium was replaced with complete growth medium containing 
10 mM sodium butyrate (Sigma-Aldrich GmbH) and the cells were incubated 
for another 21 h at 30 °C for enhanced recombinant protein production. All 
incubations were carried out in a humidified incubator set to 5 % CO2. The 
following day the cells were detached and the medium was replaced by DPBS. 
The cells from one dish were plated on one black 96-well clear-bottom cell 
culture plate (Corning B.V. Life Sciences) about an hour prior to the assay. The 
functional assays were performed on a PHERAstar plate reader (BMG 
LABTECH GmbH), with excitation at 427 nm and simultaneous dual emission 
at 480 and 530 nm. The cells were assayed in the final volume of 100 l DPBS 
upon addition of 10 X ligand solution. 
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Data analysis 
The change in FRET (ΔFRET) was calculated using equation (2): 
 
∆FRET =
ఱయబ	೙೘బ
రఴబ	೙೘బି
ఱయబ	೙೘
రఴబ	೙೘
ఱయబ	೙೘బ
బ
               Eq. (2), 
 
where 480 nm0 and 530 nm0 refer to the fluorescence emissions at the cor-
responding wavelengths before and 480 nm and 530 nm after the ligand 
treatment, respectively. Experiments were performed in at least 3 independent 
determinations in triplicates. Data analysis was performed using three parameter 
logistic function Y=Bottom+(Top-Bottom)/(1+10^((LogEC50-X))) in GraphPad 
PRISM 5.04 (GraphPad Software). Data are presented as mean pEC50  
S.E.M. 
 
  
రఴబ	೙೘
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6. RESULTS AND DISCUSSION 
[3H]cAMP competition binding assay (Nordstedt et al., 1990) was implemented 
in our laboratory by Vonk et al. (2008, 2009). This assay served as standard for 
cAMP detection and is still in use today, as a reference method at the beginning 
of projects with new GPCRs or new recombinant cell lines. However 
[3H]cAMP competition binding assay is an in vitro endpoint assay only allo-
wing detection of the analyte in cell lysates. 
The use of cAMP biosensors provides significant advantages for monitoring 
of cAMP production in real time without the need for cell lysis. Due to suitable 
affinity for cAMP (~ 1 µM), the monomolecular structure of the biosensor 
construct and its uniform distribution throughout the cytosol Epac2-camps bio-
sensor (Nikolaev et al., 2004) we selected for detection of cAMP upon GPCR 
stimulation. 
For biosensor expression we first used common transfection reagents 
Lipofectamine 2000 (Invitrogen Life Technologies) and ExGen 500 (Fer-
mentas). Inconsistent expression levels between independent assays posed 
problems for our assay development. Increases in the amount of DNA and 
lipophilic reagent caused increased cytotoxicity but did not result in higher 
protein expression. Also to perform dose-response experiments with a reason-
able amount of data points we needed high number of cells expressing the bio-
sensor. It was clear that the use of transfection reagents poorly suits the 
development of a high-throughput screening assay due to their relatively high 
cost and the constant need for large amounts of purified plasmid DNA. 
To overcome these limitations we implemented the BacMam technology. 
Epac2-camps gene under the human cytomegalovirus promotor was cloned into 
the baculovirus vector and the polyhedrin promoter sequence driving protein 
expression in insect cells was eliminated. After obtaining the virus the condi-
tions for cell transduction were optimized for the B16F10 cell line expressing 
the melanocortin MC1 receptor. We found that suitable sensor expression levels 
were achieved at multiplicity of infection of 200 to 400 and by incubation of the 
mammalian cells with baculovirus for 2 to 4 h. To enhance protein expression 
after the transduction step, sodium butyrate, a histone deacetylase inhibitor was 
used at 10 mM. Sufficient protein expression for functional assays was achieved 
24 h post-transduction and remained such for a further 24 h. It was de-
monstrated that the assay was flexible and had a convenient time frame between 
the transduction of cells and the functional measurements themselves (Paper I). 
To verify expression and functionality of the MC1 receptor in B16F10 the 
cells were stimulated with MC1R endogenous agonist melanocyte stimulating 
hormone α-MSH. The accumulated cAMP was measured using the [3H]cAMP 
competition binding assay (Figure 1). Upon 100 nM α-MSH a twofold increase 
in cAMP level was detected. Receptor activation upon stimulation with α-MSH 
alone and in presence of 100 µM IBMX (phosphodiesterase inhibitor) was 
much higher (ninefold increase over the basal cAMP level). These results 
showed that B16F10 cells are suitable for MC1R activation studies. 
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Firgure 1: Influence of a-MSH and IBMX on cAMP levels in B16F10 cells. Cells 
were treated with the ligands for 20 min at 37 °C. The accumulated cAMP was detected 
using the [3H]cAMP competition binding assay. Graph showing data from a represen-
tative experiment carried out in sextuplicates (n=2). 
 
 
After verification of MC1R expression and functionality in B16F10 cells, we 
started to develop the cAMP biosensor assay. Commonly for the cAMP accu-
mulation assays, phosphodiesterase inhibitors are used to amplify the signal. 
Accounting for phosphodiesterases, enzymes that hydrolyze cAMP to a non-
signaling AMP, is significant, because they determine the lifetime of the “effec-
tive pool” of cAMP measured in the assay (Willoughby and Cooper, 2008; Hill 
et al., 2010). Therefore we first investigated the role of inclusion of IBMX in 
the biosensor assay. It was determined that 100 µM IBMX did not affect EC50 
values for α-MSH or forskolin (a direct activator of adenylate cyclase) but the 
inhibitor did also not improve the biosensor based detection system. IBMX 
decreased the dynamic range of the assay by elevating the basal level of cAMP 
(the change in FRET signal was smaller, compared to cells assayed without 
addition of phosphodiesterase inhibitor). Compared to the in vitro assay, where 
the accumulated cAMP is measured after cell lysis, the biosensor responds to 
immediate changes in cAMP. With the use of the biosensor it was now possible 
to detect changes in cAMP concentrations in real time, without the need for 
additional signal enhancement.  
Bivalent metal cations are known to play an important role in ligand binding 
to GPCRs but the exact mechanisms still remain elusive and vary depending on 
the ion and on the receptor in question. It has been shown that Zn2+ and Ca2+ 
ions modulate binding of ligands to the MC1R (Holst et al., 2002; Kopanchuk et 
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al., 2005). To determine the effect of bivalent cations on receptor activation in 
B16F10 cells, cells were first treated with EGTA or EDTA, washed with 
phosphate buffered saline and thereafter, fixed concentrations of Ca2+ or Mg2+ 
were added to the reaction mixture. Upon removal of bivalent cations with  
1 mM EDTA, the potency of the MC1R agonists (pEC50 = 6.8 ± 0.6 for α-MSH) 
was significantly lower than in presence of bivalent cations  (Figure 2). Addition 
of 1 mM Ca2+ was found to be necessary for high-potency agonist effect  
(pEC50 = 9.2 ± 0.4), whereas 1 mM Mg2+ also increased the potency of agonists 
but to a lesser extent (pEC50 = 7.9 ± 0.1). Similar effects were observed for all 
MC1R agonist tested (Paper I). After treatment with EGTA, which binds Ca2+ 
with higher affinity than Mg2+, the obtained results were comparable to data 
observed after EDTA treatment. These results together demonstrated that the 
pEC50 values strongly depend on the ionic composition of the assay buffer. The 
effect of the bivalent cations must be caused at the step of ligand binding to 
receptor, because activation of cAMP signaling cascade is not abolished by 
their removal. In this light, all of the following experiments we carried out in 
phosphate buffered saline in the presence of 1 mM Ca2+, if not stated otherwise. 
 
 
Figure 2: The effect of Ca2+ and Mg2+ on MC1R activation by α-MSH. B16F10 
murine melanoma cells were transduced with BacMam-Epac2-camps virus for 3 h and 
further incubated for 21 h in complete growth medium supplemented with 10 mM 
sodium butyrate. Cells were washed with DPBS containing 1 mM EDTA prior to 
experiment. Chelating agents were removed and cells were assayed in DPBS (with or 
without 1 mM Ca2+ or Mg2+) upon 10 min treatment with a full agonist, α-MSH. The 
maximal FRET change was normalized to 100 % response. Without Ca2+ and Mg2+: 
pEC50 = 6.8 ± 0.6; in presence of 1 mM Mg2+: pEC50 = 7.9 ± 0.1; in presence of 1 mM 
Ca2+: pEC50 = 9.2 ± 0.4; (n=4). Graph showing data from a representative experiment. 
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The MC1 receptor activation was further characterized by a set of known MC1R 
ligands (Figure 3). In B16F10 cells all studied MC1R agonists caused a con-
centration dependent increase in cAMP concentration. α-MSH, β-MSH, NDP-α-
MSH behaved as full agonists for MC1R with similar sensor activation profiles, 
while their activation level remained 75 % of the level achieved by forskolin. 
Partial agonists (SHU-9119, MS-05, HS-024) achieved a level of 75% of full 
agonist activation (Paper I). The selective low molecular weight MC4R agonist 
I-THIQ had no effect on MC1R activation in our system. These data are in 
agreement with previously published efficacies for these ligands. It was 
demonstrated that the cAMP biosensor assay is able to distinguish between full 
and partial agonists, which is important for characterization of newly synthe-
sized ligands. In vitro cAMP accumulation assays and reporter gene assays are 
sometimes insensitive to detection of partial agonism, because of the signal 
amplification along the signaling cascade or due to measurements of the 
amplified readout. 
 
 
Figure 3: Influence of different concentrations of MC1R ligands on cAMP bio-
sensor signal in B16F10 cells. Cells were transduced with BacMam-Epac2-camps virus 
for 3 h and further incubated for 21 h in complete growth medium supplemented with 
10 mM sodium butyrate. Cells were treated with ligands for 10 min at 37 ºC. Measure-
ments were performed in DPBS + 1 mM Ca2+ for full receptor activation. The maximal 
FRET change was normalized to 100 % of the full agonist NDP-α-MSH response. 
pEC50 ± S.E.M. (n=4): NDP-α-MSH: 9.9 ± 0.4; α-MSH: 9.2 ± 0.4; β-MSH: 8.74 ± 0.06; 
SHU-9119: 8.9 ± 0.3; MS-05: 7.96 ± 0.03; HS-024: 7.27 ± 0.13; I-THIQ showed no 
activation (n=2). Graph showing data from a representative experiment. 
 
 
The study on MC1R in B16F10 cells demonstrated that the developed BacMam 
system for cAMP biosensor expression is suitable for GPCR activation studies 
and the calculated Z´-factor values > 0.6 for all MC1R specific agonists and 
forskolin confirmed its suitability for high throughput screening (Paper I). 
35 
In 2011 a third generation TEpacVV biosensor was constructed and characte-
rized by Klarenbeek et al. The sensor consists of a part of Epac1 protein fused 
between a bright fluorescent protein mTurquoise and a tandem acceptor 
consisting of two Venus proteins. The new sensor was shown to have better 
signal-to-noise ratio and dynamic range compared to previous versions of Epac 
based cAMP biosensors (Klarenbeek et al., 2011). 
The group kindly provided us with the new cDNA construct that we cloned 
into the BacMam expression vector. The BacMam viruses containing the 
TEpacVV biosensor gene were generated analogues to the work with Epac2-camp 
biosensor. After generation and optimization of the expression system, TEpacVV 
biosensor was compared the former, Epac2-camp biosensor. HEK293 cells 
stably expressing dopamine D1 receptor were transduced with BacMam viruses 
containing the gene of either of the biosensors and the cells were assayed on the 
next day. The dynamic range (FRET change window) was almost two times 
wider for the TEpacVV biosensor, but no differences in the potencies were deter-
mined from the dose-response curves obtained with two different biosensors. 
The calculated EC50 values were approximately 1µM for forskolin and 1 nM for 
dopamine (Figure 4). The small difference in the affinities of the cAMP-binding 
domains of Epac1 and Epac2 proteins used in the biosensors (Kd ~ 4 and  
1.2 µM, respectively; De Rooij et al., 2000) did not show discrepancies in the 
measured potencies for the known compounds. These data confirmed that 
switching from Epac2-based sensor to the Epac1-based biosensor for higher 
sensitivity in terms of FRET span is safe and justified. From then on TEpacVV 
biosensor was used in all of the following studies. 
 
 
Figure 4: Cellular responses to forskolin and dopamine measured with Epac2-
camps and TEpacVV biosensors. HEK293 cells stably expressing dopamine D1 recep-
tor were transduced with BacMam virus for 3 h and further incubated for 21 h in 
complete growth medium supplemented with 10 mM sodium butyrate. Cells were 
treated with adenylate cyclase activator forskolin or D1R agonist dopamine for 10 min 
at 37 ºC. Graph showing data from a representative experiment (n=2) performed in 
triplicates. 
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Dopamine has several functions in central nervous system including voluntary 
movement, feeding, affect, reward, sleep, attention, working memory, and 
learning (Beaulieu and Gainetdinov, 2011). Dopamine receptors are thus targets 
for many drugs. Although many dopaminergic ligands have been on the market 
for a long time (agonists mainly in the treatment of Parkinson’s disease and 
antagonists as antipsychotics in the treatment of schizophrenia), development of 
more selective and potent dopaminergic compounds is still of great importance 
(Reinart-Okugbeni, 2012; Beaulieu et al., 2015). It is therefore important to 
have a functional assay for characterization of potencies of dopaminergic li-
gands in parallel to ligand binding experiments. All five subtypes of dopamine 
receptors signal via the adenylate cyclase pathway. D1 and D5 receptors are 
coupled to the Gs family proteins, hence agonist binding activates cAMP 
synthesis. D2, D3 and D4 receptors are coupled to the Gi family proteins and 
upon receptor activation cAMP synthesis is inhibited. We had successfully used 
the cAMP biosensor to monitor Gs coupled receptor activation (MC1 and D1 
receptors), but now the assay system needed to be adapted for measurements of 
decreases in cAMP levels induced by Gi coupled receptor activation. 
To monitor the decrease in cellular cAMP, its cellular level is increased by 
pretreatment with a direct AC activator forskolin. The assay conditions were 
optimized by varying the concentrations of forskolin between 1 and 50 µM. 
Upon cell stimulation with 10 µM forskolin together with receptor agonist, the 
dose dependent inhibition of cAMP production was detected in the widest 
dynamic range (15–20% of FRET change). Gi coupled receptor agonist potency 
in this type of assay is described by the IC50 value (Figure 5; Paper II).  
 
Figure 5: Inhibition and activation of cAMP synthesis. HEK293 cells stably expres-
sing dopamine D1 or D3 receptor were transduced with BacMam virus for 3 h and 
further incubated for 21 h in complete growth medium supplemented with 10 mM 
sodium butyrate. HEK293-D1R cells were treated with serial dilutions of dopamine and 
the response was measured 10 minutes after agonist treatment (blue). For D3R stimu-
lation cells were treated with serial dilutions of dopamine together with 10 µM forskolin 
(direct activator of adenylate cyclase). The response was measured 10 minutes after 
agonist treatment (green). Graph showing data from a representative experiment (n=3). 
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Our general aim is to approach and study GPCR systems from different direc-
tions. In Paper II we have introduced an approach to gather and integrate expe-
rimental data from ligand binding experiments, G protein activation studies and 
measurements of the second messenger levels. The strategy relies on the two 
basic properties, experiments are being performed using baculovirus constructs 
and the detected signals are based on molecular fluorescence. In the future, we 
aim to combine different experimental readouts into new meaningful infor-
mation about the signal transduction mechanism of GPCRs. 
 Characterization of the biological activity of novel compounds requires pre-
cision and good assay reproducibility. We have provided a step-by-step protocol 
for generation and application of the BacMam based cAMP biosensor assay 
(Paper III). We also present a thorough description of a novel protocol for 
determination of virus titer with a cell size-based assay adapted and modified in 
our laboratory. To help other groups trying to set up the BacMam based 
expression system tips and observations have been included as notes at the end 
of the paper. This publication is a tool to disseminate our cumulative knowledge 
and observations in the field on cAMP detection and GPCR ligand characte-
rization. 
 In addition to the functional characterization of low-molecule weight com-
pounds and peptide ligands, the developed cAMP biosensor based assay system 
could also be applicable for studies of hormone receptors and their ligands, 
glycoproteins (Paper IV). The LH receptor is known to bind two proteins of the 
gonadotropin family, human luteinizing hormone (hLH) and human chorionic 
gonadotropin (hCG). Despite the high level of structural homology and action at 
a shared receptor, hLH and hCG have vital and unique roles in human develop-
ment and reproduction. Our objective was to examine the differences or simila-
rities of LH receptor activation by hLH and hCG. No significant differences in 
receptor activation and formation of cAMP in COS-7 cells expressing the re-
combinant LH receptor (Müller et al. 2003) were determined in this study 
during the first 120 minutes from the addition of hormones (Paper IV). The 
specificity of gonadotropin action at the LH receptor must be achieved by 
another mechanism or as a result of differences in the long-term signaling 
(Casarini et al. 2012; Choi and Smitz 2014). 
Next, the biological activity of hCG preparations of different origins were 
compared. A four times lower potency for urinary hCG (EC50=100 pM) 
compared to the recombinant hCG (EC50=25 pM) was determined (Figure 6; 
Paper IV). The difference between the measured potencies may be explained 
by the different manufacturing and the subsequent stability of the urinary 
purified hormone compared to the recombinant preparation. Also, different 
patterns of glycosylation of recombinant and urinary preparations may influence 
the detected biological activity of the hormone. Today the produced hormone 
preparations are calibrated against the international reference preparations using 
immunoassays. These assays are based on epitope detection and generally do 
not account for the proper folding of the protein. The cAMP detection based 
assay system could be an important addition for quantification of active 
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amounts/concentrations of the hormones in pharmaceutical preparations, where 
the information about the fraction of biologically active form of the protein is of 
highest importance. 
Since for evaluation of the biological activity of hormones LH receptor acti-
vation was used as the mediator of the biological signal (a natural biosensor), it 
opened a possibility to use the developed system for quantification of active 
concentrations of hCG, which is of special interest in the field of in vitro 
fertilization. 
 
 
Figure 6: Influence of different concentrations of hCG preparations on cAMP bio-
sensor signal. COS-7 cells stably expressing LH receptor were transduced with 
BacMam-TEpacVV virus for 3 h and further incubated for 21 h in complete growth 
medium supplemented with 10 mM sodium butyrate. Cells were treated with ligands for 
30 min at 37 ºC. For urinary hCG (green): EC50=100 pM; for recombinant hCG (blue): 
EC50=25 pM. Graph showing data from a representative experiment (n=4) performed in 
triplicates. 
 
 
Human chorionic gonadotropin is produced by trophoblasts, the cells that 
surround the growing human embryo and later form the placenta. Different 
isoforms of hCG (primarily hyperglycosylated hCG and the β-subunit of hCG) 
have been shown to be useful as biomarkers for embryo selection to improve 
the pregnancy chances after embryo transfer (Ramu et al. 2011; Butler et al. 
2013). Today the transplanted embryos are selected based on their morphology 
and physicians’ expertise and experience using grading systems based on the 
stage and morphological appearance of the embryo, with the success rate of 
implantation still under 50%. The high sensitivity (LOD: 5 pM or 4 mIU/mL) 
determined from a calibration curve using recombinant hCG, suggests the 
possibility to use cAMP biosensor assay for detection of hCG as a biomarker in 
the analysis of embryo spent culture media (Paper IV). The LODs of 
immunoassays used in previous quantitative studies are in the low mIU/mL 
range (Butler et al. 2013; Stenman et al. 2013; Xiao-Yan et al. 2013).  However, 
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since in the cAMP biosensor assay only the active portion of the total hormone 
concentration is eliciting a measurable response, the possibly higher total 
hormone concentration of the probe (detectable by immunoassays) may result in 
some trade-off between signal specificity and sensitivity. Addressing the 
applicability of the developed BacMam based cAMP biosensor assay for 
challenging tasks as unbiased embryo selection is subject for future studies. 
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7. CONCLUSIONS 
In summary, our studies on development and application of cAMP assays for 
monitoring of biological activity of various GPCR agonists led to the following 
conclusions: 
 
 FRET based biosensors for cAMP detection in living cells proved advanta-
geous over in vitro assays measuring the endpoint readout of accumulated 
cAMP in cell lysates. Receptor activation can be measured quantitatively
 BacMam gene delivery enables reliable and dose-adjustable expression of 
the recombinant cAMP biosensor protein in different cell lines. 
 FRET based cAMP biosensor assay is well suited for characterization of 
biological activity of GPCR ligands as it can distinguish between the full 
and partial agonists as well as antagonists in competition experiments. The 
determined Z′ factor values (>0.6) confirm assay suitability for cell-based 
high-throughput screening. 
 Bivalent metal cations are known to mediate ligand binding to melanocortin 
receptors. GPCR-mediated signal transduction (activation of cAMP sig-
naling cascade) is unaffected by the use of bivalent metal cations, however 
Ca2+ was found to be required for high-potency agonist effect on MC1R. 
Mg2+ also increased the potency of agonists but to a lesser extent. 
 It was demonstrated that cAMP biosensor assay was suitable for monitoring 
both, Gs and Gi coupled receptor activation. 
 No significant differences between LH and hCG were found in kinetics nor 
in potencies of cAMP production in COS-7 cells stably expressing the LH 
receptor. 
 Only the biologically active portion of the total hormone concentration is 
eliciting the measured response in the cAMP biosensor assay.  
 The high sensitivity of the biosensor assay allows quantitative detection of 
gonadotropins in picomolar concentration. 
 Our developed cAMP biosensor assay is a reliable tool for studies of diffe-
rent GPCRs and characterization of their ligands with various structural and 
functional properties.  
in real time. 
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8. SUMMARY IN ESTONIAN 
Tsüklilise adenosiinmonofosfaadi biosensori arendamine ja 
rakendamine G valguga seotud retseptorite  
signaaliülekande uurimiseks 
 
Maailma rahvastik on pidevas kasvus kuid ka vananemises ning sellest on 
tingitud mõnd haigust või sündroomi põdevate patsientide üha suurenev hulk. 
Enamik haigustest on põhjustatud häiretest organismi metabolismi või rakkude 
signaaliülekande regulatsioonis. G valguga seotud retseptorid (GPCR) moo-
dustavad suure rakkudevaheliste signaalide ülekannet reguleeriva valkude pere-
konna. Inimese genoomist on leitud ligi 800 erineva GPCR-i geenijärjestused. 
Keemilise signaaliülekande moduleerimine on levinud ravistrateegia, mida kin-
nitab ka tõsiasi, et ligi kolmandik kõigist tänapäeva retseptiravimitest on suu-
natud just GPCR-tele. Ravimid ehk bioaktiivsed ühendid on seega muutunud 
tänapäeva maailma asendamatuks osaks. 
Uute molekulide otsinguil on väga olulisteks ühendite molekulaarne disain, 
farmakokineetiliste parameetrite ja bioloogilise aktiivsuse määramine ning 
katsetulemuste võrdlus struktuurselt sarnaste või kehaomaste signaalimoleku-
lide omadustega. Ühendite süstemaatiliseks testimiseks on loodud mitmeid 
katsesüsteeme ning nende arendamine on väga aktuaalne ka täna. Käesolevas 
doktoritöös arendati välja katsesüsteem GPCR-te ligandide iseloomustamiseks 
lähtudes tsüklilise adenosiinmonofosfaadi (cAMP) signaaliraja aktivatsiooni 
jälgimisest. 
cAMP on signaalimolekul, mis kannab rakus edasi paljude erinevate GPCR-
de poolt vahendatud bioloogilisi teateid. Kui retseptorile seondunud ligand on 
aktiveeriva iseloomuga, suureneb või väheneb rakus cAMP sünteesi eest vastu-
tavate ensüümide adenülaadi tsüklaaside aktiivsus ning muutus cAMP kont-
sentratsioonis on võrdeline retseptori aktivatsiooniga. Rakendades cAMP suhtes 
tundlikke ja spetsiifilisi sensoreid, on võimalik jälgida retseptorile seostuvate 
ligandide bioloogilist aktiivsust elusrakkudes reaalajas. Käesolevas töös kasu-
tatud biosensorid koosnevad cAMP siduvast peptiidijärjestusest ning kahest 
erinevate spektraalsete omadustega fluorestsentsvalgust. Puhkeolekus toimub 
kahe fluorofoori vahel Försteri resonantsenergia ülekanne (FRET). Ergastades 
biosensori fluorofoore kindla lainepikkusega valgusega (430 nm) on resonants-
energia ülekande tulemusena võimalik määrata mõlema fluorofoori poolt kiira-
tava valguse intensiivsust lainepikkustel 480 ja 530 nm. cAMP taseme suurene-
misel rakus seostub signaalimolekul sensorile ning muudab fluorofooride oma-
vahelist kaugust ja orientatsiooni võrreldes puhkeolekuga. Selle tulemusena 
väheneb fluorestsentsvalkude vaheline FRET ning muutub vastavatel laine-
pikkustel detekteeritava valguse intensiivsuste suhe. FRET-l põhineva bio-
sensoriga on seega võimalik mõõta cAMP muutust elusrakkudes vastusena raku 
pinnal asuvate retseptorite aktivatsioonile. 
Biosensorite kasutamiseks on vajalik nende ekspressioon (rakud peaksid 
tootma sensorvalku ise, lähtudes seda kodeerivast geenijärjestusest). Saavuta-
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maks biosensori ühtlast ekspressiooni erinevates uuritavates rakkudes loodi 
käesolevas töös bakuloviirustel põhinev BacMam ekspressioonisüsteem. Inime-
sele ohutud putukaviirused transpordivad sensorit kodeeriva geenijärjestuse 
uuritavasse rakku, kus sellest sünteesitakse cAMP biosensorvalk. BacMam 
süsteem võimaldas reguleerida biosensori ekspressioonitaset, mille tulemuseks 
oli ühtlane ja hea korratavusega ekspressioon, mis lõi eelduse usaldusväärse 
katsesüsteemi loomiseks. 
Töö käigus ekspresseeriti cAMP biosensorit mitmetes erinevates rakuliinides 
ning uuriti kolme erineva GPCR-i aktivatsiooni (melanokortiinne retseptor 
MC1R, dopamiini retseptor D1R ning inimese koorioni gonadotropiini ja luteni-
seeriva hormooni LH retseptor). Need retseptorid seovad struktuurselt väga 
erinevaid ligande. MC1 retseptori ligandideks on peptiidid, D1 retseptor seob 
madalmolekulaarseid ühendeid ja LH retseptori ligandideks on mitmekümne 
kilodaltoni suurused glükoproteiinidest hormoonid. Leiti, et FRET sensoril 
põhinev katsesüsteem on sobilik kõigi nende GPCR-de ligandide bioloogilise 
aktiivsuse iseloomustamiseks, kusjuures süsteem võimaldab eristada nii osalisi 
kui ka täisagoniste (aktivaatoreid). Kuna loodud katsesüsteem on rakendatav nii 
cAMP tõusu kui languse määramiseks, siis võimaldas see määrata ka erinevate 
dopamiini retseptorite alatüüpe, mis nii aktiveerivad kui ka inhibeerivad 
ensüümi adenülaadi tsüklaas. Lisaks ligandide endi aktivatsioonile võimaldas 
katsesüsteem määrata ka ligandi seostumist moduleerivate komponentide mõju. 
Näidati, et 1 mM Ca2+ või Mg2+ on vajalikud, et peptiidsed agonistid oleksid 
MC1 retseptoril efektiivsed. Katsesüsteemi tundlikkus (avastamispiir 5 pM) 
võimaldab seda kasutada aktiivsete hormoonide hulga määramiseks erinevates 
bioloogilistes proovides. 
Käesolevas töös arendati välja FRET biosensoril põhinev katsesüsteem G 
valguga seotud retseptorite poolt reguleeritava cAMP taseme määramiseks 
elusrakkudes. Töö tulemusena on loodud tööriist, mille abil on võimalik mää-
rata erinevate struktuursete omadustega ühendite bioloogilist aktiivsust vasta-
vate retseptorite aktivatsiooni kaudu. 
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